Some of the world''s most successful investors can''t get enough of The Trade Desk, Shockwave Medical, and SoFi Technologies.
SANTA CLARA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 34th Annual Virtual Healthcare Conference, scheduled to be held from November 29 to December 1, 2022.
As of Monday, ShockWave Medical Inc.’s (NASDAQ:SWAV) stock closed at $243.19, down from $246.60 the previous day. While ShockWave Medical Inc. has underperformed by -1.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWAV rose by 11.73%, with highs and lows ranging from $320.54 to $113.36, […]
ShockWave Medical Inc. (SWAV)’s stock has witnessed a price declined of -9.23% from the previous close with its current price standing at $251.82. Its current price is -21.44% under its 52-week high of $320.54 and 122.14% more than its 52-week low of $113.36. Based on the past 30-day period, the stock price is -22.60% below […]
Alger Capital, an investment management company, released its “Alger Small Cap Focus Fund” third quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the fund outperformed the Russell 2000 Growth Index. Consumer discretionary and industrial sectors contributed to the fund’s relative performance in the quarter, while healthcare and energy […]
SWAV earnings call for the period ending September 30, 2022.
ShockWave Medical, Inc. (NASDAQ:NASDAQ:SWAV) Q3 2022 Earnings Conference Call November 07, 2022 04:30 PM ET Company Participants Debbie Kaster - Vice President, Investor Relations Doug…
Shockwave Medical Earnings, Revenue Beat in Q3
ShockWave Medical press release (SWAV): Q3 GAAP EPS of $0.92 beats by $0.24.Revenue of $131.3M (+101.5% Y/Y) beats by $7.51M.Shares -6.3%.Cash, cash equivalents and…
SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022.
ShockWave Medical (NASDAQ: SWAV ) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here''s what investors need to know before the announcement. Analysts estimate that ShockWave Medical will report an earnings per share (EPS) of $0.67. ShockWave Medical bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
ShockWave Medical Inc. (NASDAQ:SWAV) marked $296.82 per share on Wednesday, up from a previous closing price of $295.31. While ShockWave Medical Inc. has overperformed by 0.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWAV rose by 39.84%, with highs and lows ranging from $314.90 to […]
Related Stocks: SWAV ,
SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Although, on the surface, everything looks gloomy now for stocks, one point that the bears are forgetting, I would argue, is that we live in an era of unprecedented technological advancement. Never before in the world has there simultaneously been so many new, highly impactful technologies –from artificial intelligence to connected cars to fintech to autonomous vehicles to automated retail checkout devices. As a result, there are a diversity of companies that are little known today but whose products will generate tremendous amounts of revenue in two or three years. And, of course, the shares of these companies will go up hundreds of percent along the way, making them great stocks to buy at this point. Let’s take a look at seven little-known stocks to buy that can make those who buy a few thousand dollars of their shares today, millionaires in a decade. ICAD iCAD $1.91 EMBK Embark $6.45 GEVO Gevo $2.10 SWAV Shockwave Medical $273.94 YETI YETI Holdings $30.65 ARRY Array Technologies $16.38 DV DoubleVerify $28.51 iCAD (ICAD) Source: shutterstock.com/Peshkova iCAD (NASDAQ: ICAD ) develops products that use artificial intelligence to detect cancer more effectively and efficiently than standard-of-care products.
IBD Stock Of The Day Shockwave Medical is cracking deeper into the calcium game, and taking SWAV stock to new highs.
ShockWave Medical is currently executing on all cylinders, but SWAV stock''s valuation has gotten excessive. Click here to read why.
As the market shows signs of a rebound, Vertex, Enphase and Shockwave Medical are among 25 stocks to watch.
PARIS, FRANCE and BOSTON, MA / ACCESSWIRE / September 26, 2022 / TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has appointed Sara Toyloy as its fourth independent member of the Board of Directors. Ms. Toyloy has over 30 years of experience in the medical device industry. In 2020, she founded Fabrica Consulting LLC, a medical device consulting firm providing global regulatory and clinical trial strategies, where she currently serves as president. Prior to this, she was at Elixir Medical Corporation for nearly 12 years, where she held several executive positions including President of New Therapies and Chief Regulatory Officer and Executive Vice President of Regulatory, Clinical and Quality. She also served as Executive Vice President of Biosensors International Group, and Vice President of Regulatory and Clinical Affairs at Medtronic Vascular. Ms. Toyloy began her career at Guidant Corporation (acquired by Boston Scientific in 2006) where she held several key roles, ultimately serving as Guidant''s Director of Regulatory Affairs and Clinical Research.